Rezatapopt

Overview

Rezatapopt (PC14586) is an orally active antineoplastic agent. Rezatapopt binds to a pocket created by the TP53 Y220C mutation. Rezatapopt restores p53 tumor suppressor functions by stabilization of the p53 protein structure. Rezatapopt demonstrates tumor inhibition and regression in mouse models with established human tumor xenografts harboring the TP53 Y220C mutation.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MDM-2/p53

Product Information

• Catalog No.: HY-156633
• CAS No.: 2636846-41-6
• Molecular Formula: C28H31F4N5O2
• Molecular Weight: 545.57
• Purity: 99.62%
• Storage: 4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (4.58 mM); Suspended solution
• Availability: In-stock

Source

Original product source